Suppr超能文献

XEC变体:基因组进化、免疫逃逸及对公共卫生的影响

The XEC Variant: Genomic Evolution, Immune Evasion, and Public Health Implications.

作者信息

Aljabali Alaa A A, Lundstrom Kenneth, Hromić-Jahjefendić Altijana, El-Baky Nawal Abd, Nawn Debaleena, Hassan Sk Sarif, Rubio-Casillas Alberto, Redwan Elrashdy M, Uversky Vladimir N

机构信息

Department of Pharmaceutics and Pharmaceutical Technology, Faculty of Pharmacy, Yarmouk University, Irbid 21163, Jordan.

PanTherapeutics, Rte de Lavaux 49, CH1095 Lutry, Switzerland.

出版信息

Viruses. 2025 Jul 15;17(7):985. doi: 10.3390/v17070985.

Abstract

Narrative review synthesizes the most current literature on the SARS-CoV-2 XEC variant, focusing on its genomic evolution, immune evasion characteristics, epidemiological dynamics, and public health implications. To achieve this, we conducted a structured search of the literature of peer-reviewed articles, preprints, and official surveillance data from 2023 to early 2025, prioritizing virological, clinical, and immunological reports related to XEC and its parent lineages. Defined by the distinctive spike protein mutations, T22N and Q493E, XEC exhibits modest reductions in neutralization in vitro, although current evidence suggests that mRNA booster vaccines, including those targeting JN.1 and KP.2, retain cross-protective efficacy against symptomatic and severe disease. The XEC strain of SARS-CoV-2 has drawn particular attention due to its increasing prevalence in multiple regions and its potential to displace other Omicron subvariants, although direct evidence of enhanced replicative fitness is currently lacking. Preliminary analyses also indicated that glycosylation changes at the N-terminal domain enhance infectivity and immunological evasion, which is expected to underpin the increasing prevalence of XEC. The XEC variant, while still emerging, is marked by a unique recombination pattern and a set of spike protein mutations (T22N and Q493E) that collectively demonstrate increased immune evasion potential and epidemiological expansion across Europe and North America. Current evidence does not conclusively associate XEC with greater disease severity, although additional research is required to determine its clinical relevance. Key knowledge gaps include the precise role of recombination events in XEC evolution and the duration of cross-protective T-cell responses. New research priorities include genomic surveillance in undersampled regions, updated vaccine formulations against novel spike epitopes, and long-term longitudinal studies to monitor post-acute sequelae. These efforts can be augmented by computational modeling and the One Health approach, which combines human and veterinary sciences. Recent computational findings (GISAID, 2024) point to the potential of XEC for further mutations in under-surveilled reservoirs, enhancing containment challenges and risks. Addressing the potential risks associated with the XEC variant is expected to benefit from interdisciplinary coordination, particularly in regions where genomic surveillance indicates a measurable increase in prevalence.

摘要

叙述性综述综合了关于SARS-CoV-2 XEC变体的最新文献,重点关注其基因组进化、免疫逃逸特征、流行病学动态以及对公共卫生的影响。为此,我们对2023年至2025年初的同行评审文章、预印本和官方监测数据进行了结构化检索,优先考虑与XEC及其亲本谱系相关的病毒学、临床和免疫学报告。XEC由独特的刺突蛋白突变T22N和Q493E定义,尽管目前的证据表明包括针对JN.1和KP.2的mRNA加强疫苗对有症状和严重疾病仍具有交叉保护效力,但XEC在体外的中和作用略有降低。SARS-CoV-2的XEC毒株因其在多个地区的流行率不断上升以及取代其他奥密克戎亚变体的潜力而受到特别关注,尽管目前缺乏其复制适应性增强的直接证据。初步分析还表明,N端结构域的糖基化变化增强了感染性和免疫逃逸能力,这有望解释XEC流行率上升的原因。XEC变体仍在出现,其特点是独特的重组模式和一组刺突蛋白突变(T22N和Q493E),这些突变共同显示出在欧洲和北美的免疫逃逸潜力增加和流行病学传播范围扩大。目前的证据并未确凿地将XEC与更高的疾病严重程度联系起来,尽管还需要进一步研究来确定其临床相关性。关键的知识空白包括重组事件在XEC进化中的精确作用以及交叉保护性T细胞反应的持续时间。新的研究重点包括在采样不足地区进行基因组监测、针对新的刺突表位更新疫苗配方以及监测急性后遗症的长期纵向研究。计算建模和“同一个健康”方法(将人类和兽医学科结合起来)可以加强这些努力。最近的计算结果(全球流感共享数据库,2024年)表明,XEC在监测不足的宿主中有进一步突变的潜力,这增加了控制的挑战和风险。应对与XEC变体相关的潜在风险预计将受益于跨学科协调,特别是在基因组监测表明流行率有可测量增加的地区。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验